Erreka Medical acquires Microliquid to expand in the healthcare sector

Erreka has taken a new step in its growth strategy with Erreka Medical, its healthcare division, following the integration of the assets and team of the biotechnology firm Microliquid in Arrasate. With this move, the group reinforces its commitment to high value-added sectors and opens a new line of business with a focus on growth.

The CEO of the Erreka Group, Arkaitz Etxezarreta, frames this operation within the context of the group’s evolution: “In line with Erreka’s growth strategy, we have incorporated the assets and staff of Microliquid, enabling us to create Erreka Medical and move towards becoming a larger entity.” The integration also involves consolidating a new area that complements the group’s current activities.

“In line with Erreka’s growth strategy, we have incorporated the assets and staff of Microliquid, enabling us to create Erreka Medical and move towards becoming a larger entity.”

Gorka Mendiaraz will head up the division; he identifies visibility as one of the main challenges: “Our biggest challenge is visibility; until now we haven’t been very well known in this field and we need to grow so that the market becomes aware of our capabilities.”

Growing in capabilities and market position

The integration of Microliquid will enable Erreka to take a leap forward in its value proposition, moving towards more complex products. “We are moving from offering simpler parts to developing much more complex components that incorporate scientific and biological capabilities,” explains Mendiaraz.

Furthermore, the cooperative has set itself ambitious medium-term goals, such as achieving a turnover of €5 million by 2028 and expanding its customer base, making the leap towards established companies in the biomedical sector.

Furthermore, the cooperative has set itself ambitious medium-term goals, such as achieving a turnover of €5 million by 2028.

Challenges: brand awareness, growth and added value

Among Erreka Medical’s main challenges are improving brand awareness and market positioning within the healthcare sector, as well as advancing along the value chain. The aim is to evolve from component manufacturing towards a model of providing complete solutions, thereby increasing the added value of its business.

At the same time, the new division will work on developing new business lines linked to microfluidics and medical devices, strengthening its technological and scientific capabilities.

“We want to become a major player in this sector and gain increasing recognition,” concludes Mendiaraz, setting the course for a division that is born with ambitions for growth and a vision for the future.

Photo gallery of the presentation: https://www.flickr.com/photos/tulankide/albums/72177720333452312